Merck & Company, Inc. (new) (MRK)
MRK moved a median of +0.02% 30 minutes after news, and +0.14% by the close. How MRK actually reacts to news — the realized, point-in-time move the market made, measured across 1,319 labeled events over the last three years with zero look-ahead.
MRK’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.01% | 47% | 1,318 |
| 30-min | +0.02% | 51% | 1,319 |
| 60-min | +0.01% | 50% | 1,319 |
| to close | +0.14% | 54% | 1,307 |
| Middle 50% of MRK reactions | -0.41% to +0.55% |
|---|---|
| Median reaction (30-min) | +0.02% |
| Measured reactions | 1,319 |
Half of all Merck & Company, Inc. (new) news events land between -0.41% and +0.55% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MRK reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 39 | +0.36% | 67% | +0.31% |
| Analyst downgrades | 35 | -0.09% | 40% | -0.87% |
| Coverage initiations | 28 | +0.01% | 50% | -0.17% |
| Rating reiterations | 126 | +0.06% | 56% | -0.04% |
| Price-target raises | 47 | +0.07% | 62% | -0.08% |
| Price-target cuts | 26 | -0.16% | 39% | -0.20% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how MRK ranks against every other measured name →
That’s how MRK usually reacts — get an email when it moves on news →Email me when MRK moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MRK's baseline. Nothing else.
Recent MRK events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Merck & Co., Inc. For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | +0.24% | -0.43% | |
| Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026 | Press release | Business Wire | -0.09% | -2.65% | |
| Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors | Press release | Business Wire | -0.09% | -2.65% | |
| Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 | Press release | Business Wire | +0.43% | +0.08% | |
| Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 | Press release | Business Wire | -0.14% | -0.62% | |
| Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) | Press release | Business Wire | -0.40% | -2.56% | |
| CAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program | Press release | Canada Newswire | +0.62% | +0.70% | |
| Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor | Press release | Business Wire | +0.62% | +0.70% | |
| Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn | Press release | Business Wire | +0.62% | +0.70% | |
| U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) | Press release | Business Wire | +0.82% | +0.49% | |
| Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema | Press release | Business Wire | +1.18% | -0.02% | |
| U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) | Press release | Business Wire | -0.09% | +1.49% | |
| Merck Canada Partners with the Montreal Museum of Fine Arts to Present the North American Premiere of Chiharu Shiota: The Soul Trembles | Press release | Canada Newswire | +0.83% | +2.24% | |
| Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan | Press release | Business Wire | +0.83% | +2.24% | |
| Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV | Press release | Business Wire | +0.48% | -0.08% | |
| Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) | Press release | Business Wire | +0.48% | -0.08% | |
| Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | Business Wire | -1.05% | +0.03% | |
| Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference | Press release | Business Wire | +1.07% | +0.65% | |
| Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma | Press release | Business Wire | +0.11% | +3.48% | |
| Form 10-Q Merck & Co., Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.77% | — | |
| Form 13F-HR Merck & Co., Inc. For: Jun 30 | SEC filing · Form 13F-HR | SEC EDGAR | +0.77% | — | |
| U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season | Press release | Business Wire | -0.73% | -1.98% | |
| Health Canada Approves KEYTRUDA® for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after ra | Press release | Canada Newswire | +0.03% | -1.79% | |
| Form 8-K Merck & Co., Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -2.21% | -0.94% | |
| Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline | Press release | Business Wire | -2.21% | -0.94% | |
| Merck Announces Fourth-Quarter 2026 Dividend | Press release | Business Wire | +0.35% | -0.10% | |
| Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development | Press release | Business Wire | -0.15% | +0.12% | |
| Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer | Press release | PR Newswire | -0.00% | +0.35% | |
| Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia | Press release | Business Wire | +1.38% | +2.66% | |
| KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy | Press release | Business Wire | -0.09% | -0.14% | |
| Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026 | Press release | Business Wire | -0.09% | -0.14% | |
| FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC) | Press release | Business Wire | -0.01% | +0.22% | |
| Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 | Press release | Business Wire | -0.66% | -2.06% | |
| Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV | Press release | Business Wire | -0.41% | +1.32% | |
| FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS =10) Advanced Triple-Negative Breast Cancer (TNBC) | Press release | Business Wire | +0.40% | +2.95% | |
| European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer | Press release | Business Wire | -0.18% | -0.73% | |
| Form 11-K Merck & Co., Inc. For: Dec 31 | SEC filing · Form 11-K | SEC EDGAR | +0.09% | -0.54% | |
| Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market | Press release | GlobeNewswire | -0.18% | -0.73% | |
| Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) | Press release | Business Wire | -0.24% | +1.04% | |
| U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease | Press release | Business Wire | -0.57% | -0.58% | |
| Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages | Press release | Business Wire | +0.06% | +0.82% | |
| FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC) | Press release | Business Wire | -2.22% | -2.39% | |
| Merck Animal Health to Acquire TARGAN | Press release | Business Wire | -0.08% | +0.39% | |
| PDA Announces Glenn E. Wright is Stepping Down as CEO & President on June 30, 2026; Craig Elliott Assuming Role Effective July 1, 2026 | Press release | PR Web | +0.03% | -0.37% | |
| Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study | Press release | Business Wire | -0.62% | -0.26% | |
| Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity | Press release | Canada Newswire | +0.76% | -0.78% | |
| Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | Business Wire | +0.95% | +0.76% | |
| FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) | Press release | Business Wire | +0.17% | -1.01% | |
| Form SD Merck & Co., Inc. | SEC filing · Form SD | SEC EDGAR | +0.01% | -0.08% | |
| Form 8-K Merck & Co., Inc. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | -1.01% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MRK section they belong to.
Where else MRK is measured.
MRK earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MOMENTA PHARMACEUTICALS (MNTA) | 1,355 | 0.00% | 46% |
| Clovis Oncology, Inc. (CLVS) | 1,349 | -0.20% | 47% |
| Humana Inc. (HUM) | 1,306 | +0.02% | 51% |
| WELLCARE HEALTH PLANS (WCG) | 1,292 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Merck & Company, Inc. (new)'s median reaction calculated?
Every labeled MRK news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,319 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of MRK's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MRK's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.